The link between nuchal translucency and congenital heart disease

Open access

Abstract

The nuchal translucency is defined as a transient subcutaneous collection of fluid behind the fetal neck seen on ultrasonography at 11-14 weeks of gestation. In this current overview it was observed the relationship between increased nuchal translucency (NT) and fetal heart structure and function in chromosomally normal fetuses. Fetuses with an increases NT have an increased risk for congenital heart disease (CHD) and the combination between an increases NT, tricuspid regurgitation (TR) and an abnormal ductus venosus (DV) Doppler flow profile is a strong marker for CHD.

References
  • 1. Nicolaides K.H., Azar G., Byrne D., Mansur C. & Marks K. (1992). Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 304, 867 - 869

  • 2. Pajkrt E., Bilardo C.M., van Lith J.M.M., Mol B.W.J. & Bleker O.P. (1995). Nuchal translucency measurement in normal fetuses. Obstet Gynecol. 86, 994 - 997

  • 3. Pandya P.P., Snijders R.J.M., De Johnson S.P., Luordes N.M. & Nicolaides K.H. (1995). Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-11 weeks of gestation. Br J Obstet Gynaecol. 102, 957 - 962

  • 4. Bilardo CM , Muller MA , Pajkrt E , Clur SA , van Zalen MM , Bijlsma EK . 2007 . Increased nuchal translucency and normal Karyotype : time for prenatal reassurance . Ultrasound Obstet Gynecol 30 : 11 - 18 .

  • 5. Souka A.P., Von Kaisenberg C.S., Hyett J.A., Snoek J.D. & Nicolaides K.H. (2005). Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol. 192, 1005 - 1021

  • 6. Westin M., Saaltvedt S., Bergman G., Almstrom H., Grunewald C. & Valentin L. (2007) . By how much does increased nuchal transluncency increased the risk of adverse outcome in chromosomally normal fetuses? A study of 16Is measurement of nuchal translucency thickness a useful screening tool for heart defects? A study of 16260 fetuses derived from an unselected pregnant population. Ultrasound Obstet Gynecol. 29, 150 - 158

  • 7. Hyett J., Perdu M., Sharland G.K., Snijders R. & Nicolaides K.H. (1999). Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ. 318, 81 - 85

  • 8. Makrydimas G., Sotiriadis A. & Ioannidis J.P. (2003). Screening performance of first - trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol. 189, 1330 - 1335

  • 9. Simpson L.L., Malone F.D., Saade G.R. & D’Alton M.E. (2007). Nuchal translucency and the risk of congenital heart disease . Obstet Gynecol. 109, 1456 - 1457

  • 10. Hyett J., Snoek J. & Nicolaides K.H. (2007). Nuchal translucency and the risk of congenital heart disease. (Letter to editor). Obstet Gynecol. 109, 1455 - 1456

  • 11. Ghi T., Huggon I.C., Zosmer N. & Nicolaides K.H. (2001). Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasoung Obstet Gynecol. 18, 610 - 614

  • 12. Makrydimas G., Sotiriadis A. & Huggon I.C. et al. (2005). Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers. Am J Obstet Gynecol. 192, 89 - 95

  • 13. Hyett J. (2004). Does nuchal translucency have a role in fetal cardiac screening? Prenat Diagn. 24, 1130 - 1135

  • 14. Galindo A., Comas C. & Martinez J.M. et al. (2003). Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10 - 14 weeks gestation. J Matern Fetal Neonatal Med. 13, 163 - 170

  • 15. Clur S.A., Mathijssen I.B. & Pajkrt E. et al. (2008). Structural heart defects associated with an increased nuchal translucency: 9 years’ experience in a referral center. Prenat Diagn. 28, 347 - 354

  • 16. Moll B.W.J. (1999). Down’s syndrome, cardiac anomalies and nuchal translucency. Fetal heart failure might link nuchal translucency and Down’s syndrome. BMJ. 318(7176), 70-71

  • 17. Hyett J., Brizot M.L., von Kaisenberg C.S., McKie A.T., Farzaneh F. & Nicolaides K.H. (1996). Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses. Obstet Gynecol. 87, 506 -510

  • 18. Nicolaides K.H., Heath V. & Cicero S. (2002). Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn. 22, 308 - 315

  • 19. Matias A., Huggon I., Areias J.C., Montenegro N. & Nicolaides K.H. (1999). Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks. Ultrasound Obstet Gynecol. 14, 307 - 310

  • 20. Allan L.D. (2006). The mystery of nuchal translucency. The Mannheimer Lecture. Cardiol Young. 16, 11 - 17

  • 21. Leiva M.C., Tolosa J.E. & Binotto C.N. et al. (1999). Fetal cardiac development and haemodynamics in the first trimester. Ultrasound Obstet Gynecol. 14, 167 - 174

  • 22. Haak M.C., Twisk J.W., Bertelings M.M., Gittenberger de Groot A.C. & van Vugt J.M. (2005). First trimester fetuses with increased nuchal translucency do not show altered intracardiac flow velocities. Ultrasound Obstet Gynecol. 25, 246 - 252

  • 23. Sedmera D., Cook A.C., Shirali G. & McQuinn T.C. (2005). Current issues and perspectives in hypoplasia of the left heart. Cardiol Young. 15, 56 - 72

  • 24. Oh C., Harmam C. & Baschat A.A. (2007). Abnormal first trimester ductus venosus blood flow: a risk for adverse outcome in fetuses with normal nuchal translucency. Ultrasound Obstet Gynecol. 30, 192 - 196

  • 25. Huisman T.W.A. & Bilardo C. (1997). Transient increase in nuchal translucency thickness and reverse end - diastolic ductus venosus flow in a fetus with trisomy 18. Ultrasound Obstet Gynecol. 10, 397 - 399

  • 26. Matias A., Gomes C., Flack N., Montenegro N. & Nicolaides K.H. (1998). Screening for chromosomal abnormalities at 10 - 14 weeks: the role of the ductus venous blood flow. Ultrasound Obstet Gynecol 12, 380 - 384

  • 27. Maiz N., Plasencia W., Dagklis T., Faros E. & Nicolaides K.H. (2008). Ductus venosus Doppler in fetuses with cardiac defects and high nuchal translucency thickness. Ultrasound Obstet Gynecol. 31, 256 - 260

  • 28. Simpson J.M. & Sharland G.K. (2000). Nuchal translucency and congenital heart defects: heart failure or not? Ultrasound Obstet Gynecol 16, 30 - 36

  • 29. Huggon I.C., Turan O. & Allan L.D. (2004). Doppler assessment of cardiac function at 11-14 weeks’ gestation in fetuses with normal and increased nuchal translucency. Ultrasound Obstet Gynecol. 24, 390 - 398

  • 30. Faiola S., Tsoi E., Huggon I.C., Allan L.D. & Nicolaides K.H. (2005). Likelihood ratio for trisomy 21 in fetus with tricuspid regurgitation at 11 to 13 + 6 weeks scan. Ultrasound Obstet Gynecol. 26, 22 - 27

  • 31. Huggon I.C., DeFigueiredo D.B. & Allan L.D. (2003). Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11 - 14 weeks of gestation. Heart. 89, 1071 - 1073

  • 32. Rudolph A.M. (2001). Congenital Diseases of the Heart (2nd ed). (pp. 3-44). New York: Futura Publishing Company

  • 33. Coceani F., Adeagbo A.S., Cutz E. & Olley P.M. (1984). Autonomic mechanism in the ductus venosus of the lamb. Am J Physiol. 247, H17 - H24

  • 34. Carmeliet P. (2003). Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet. 4, 710 - 720

  • 35. Kirby M.L. (1991). Neural crest and the morphogenesis of the Down syndrome with special emphasis on cardiovascular development. Prog Clin Biol Res. 373, 215 - 225

  • 36. Yagel S., Cohen S.M. & Messing B. (2007). First trimester fetal heartscreening. Curr Opin Gynecol. 19, 183 - 190

  • 37. Carvalho J.S. (2004). Fetal heart scanning in the first trimester. Prenat Diagn. 24, 1060 - 1067

  • 38. Lee W., Allan L. & Carvalho J.S. et al. (2008). ISUOG consensus statement: what constitutes a fetal echocardiogram? Ultrasound Obstet Gynecol. 32, 239 - 242

  • 39. Johnson B. & Simpson L.L. (2007). Screening for congenital heart disease: A move toward earlier echochardiography. Am J Perinatol. 24, 449 - 456

  • 40. Bronshtein M., Zimmer E.Z. & Blazer S. (2008). The utility of detailed first trimester ultrasound examination in abnormal fetal nuchal translucency. Prenat Diagn. 28, 1037 - 1041

ARS Medica Tomitana

The Journal of "Ovidius" University of Constanta

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 72 72 50
PDF Downloads 12 12 7